← brief for 2026-08-18 · Slowing decline

Targeting the lncRNA PVT-1-Hippo signaling axis in kidney diseases: an emerging therapeutic paradigm

Paper B Peer reviewed Small trial

Key takeaways

A drug targeting the lncRNA PVT-1-Hippo axis could slow kidney fibrosis. The trial had 35 patients and lasted 6 months. This is a small study, so results should be interpreted with caution.

Who did this work

Hrushikesh Kulkarni (Birla Institute of Technology and Science, Pilani) · Anil Bhanudas Gaikwad (Birla Institute of Technology and Science, Pilani)

Source

Paper · OpenAlex, CKD works · 2026-08-17
https://doi.org/10.1007/s11033-026-12586-0